Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma

Tanya M. Laidlaw, Claus Bachert, Nikhil Amin, Martin Desrosiers, Peter W. Hellings, Joaquim Mullol, Jorge F. Maspero, Philippe Gevaert, Mei Zhang, Xuezhou Mao, Asif H. Khan, Siddhesh Kamat, Naimish Patel, Neil M.H. Graham, Marcella Ruddy, Heribert Staudinger, Leda P. Mannent

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) and type 2 asthma share the same inflammatory pathophysiology and are frequent comorbidities. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin 4 and interleukin 13, which are key and central drivers of type 2 inflammation. Objective: We report the effect of dupilumab vs placebo on outcome measures of the upper and lower airways and health-related quality of life (HRQoL) in the pooled population of patients with CRSwNP and comorbid asthma from the phase 3 SINUS-24 (NCT02912468) and SINUS-52 (NCT02898454) studies. Methods: In these randomized, double-blind, placebo-controlled trials, patients received subcutaneous dupilumab 300 mg (n = 438) or placebo (n = 286) every 2 weeks on a background of mometasone furoate nasal spray. Changes from baseline at week 24 in the upper and lower airway outcome measures are reported. Results: Of the 724 patients randomized, 428 (59.1%) had comorbid asthma. In patients with asthma at week 24, dupilumab vs placebo improved the nasal polyp score (−2.04), patient-reported nasal congestion score (−1.04), Lund-Mackay computed tomography scan score (−6.43), peak nasal inspiratory flow (46.15 L/min), and 22-item sinonasal outcome test score (−21.42; all P < .001). The forced expiratory volume in 1 second and 6-item asthma control questionnaire scores were also markedly improved with dupilumab vs placebo. The most common adverse events (nasopharyngitis, headache, injection-site erythema, worsening of nasal polyposis, and asthma) were more frequent with placebo than dupilumab. Conclusion: Dupilumab improved upper and lower airway outcome measures and HRQoL in patients with severe CRSwNP and comorbid asthma and was well tolerated. Trial Registration: ClinicalTrials.gov Identifiers: NCT02912468 (SINUS-24) and NCT02898454 (SINUS-52).

Original languageEnglish
Pages (from-to)584-592.e1
JournalAnnals of Allergy, Asthma and Immunology
Volume126
Issue number5
DOIs
StatePublished - May 2021

Fingerprint

Dive into the research topics of 'Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma'. Together they form a unique fingerprint.

Cite this